BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
1.700
+0.030 (1.80%)
At close: Aug 13, 2025, 4:00 PM
1.720
+0.020 (1.18%)
Pre-market: Aug 14, 2025, 9:12 AM EDT
BioVie Employees
BioVie had 14 employees as of June 30, 2024. The number of employees decreased by 4 or -22.22% compared to the previous year.
Employees
14
Change (1Y)
-4
Growth (1Y)
-22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,383,088
Market Cap
13.35M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BIVI News
- 17 hours ago - BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes - GlobeNewsWire
- 6 days ago - BioVie Inc. Announces Pricing of $12 Million Public Offering - GlobeNewsWire
- 21 days ago - BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology - GlobeNewsWire
- 23 days ago - BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors - GlobeNewsWire
- 7 weeks ago - BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD) - GlobeNewsWire
- 7 weeks ago - BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress - GlobeNewsWire
- 3 months ago - BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 - GlobeNewsWire
- 5 months ago - BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025 - GlobeNewsWire